Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Seer (Nasdaq: SEER), a company focused on proteomic insights, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's management will engage in a fireside chat on September 9th at 12:20 PM ET.
Investors can access the presentation through a live webcast on the Investor section of Seer's website at investor.seer.bio. An archived version of the presentation will be made available after the conference.
Seer (Nasdaq: SEER), azienda focalizzata sulle informazioni proteomiche, ha annunciato la sua partecipazione alla Morgan Stanley 23rd Annual Global Healthcare Conference di New York. La direzione terr脿 una conversazione informale (fireside chat) il 9 settembre alle 12:20 ET.
Gli investitori potranno seguire la presentazione tramite webcast in diretta nella sezione Investor del sito di Seer all'indirizzo investor.seer.bio. Una versione archiviata della presentazione sar脿 resa disponibile dopo la conferenza.
Seer (Nasdaq: SEER), una empresa centrada en conocimientos prote贸micos, ha anunciado su participaci贸n en la Morgan Stanley 23rd Annual Global Healthcare Conference en Nueva York. La direcci贸n participar谩 en una conversaci贸n informal (fireside chat) el 9 de septiembre a las 12:20 PM ET.
Los inversores podr谩n acceder a la presentaci贸n mediante una transmisi贸n en directo (webcast) en la secci贸n Investor del sitio web de Seer en investor.seer.bio. Despu茅s de la conferencia se dispondr谩 de una versi贸n archivada de la presentaci贸n.
Seer (Nasdaq: SEER), 雼氨歆堨泊頃� 鞚胳偓鞚错姼鞐� 欤茧牓頃橂姅 旮办梾鞚� 雺挫殨鞐愳劀 鞐措Μ電� Morgan Stanley 23rd Annual Global Healthcare Conference鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 瓴届榿歆勳潃 9鞗� 9鞚� 鞓ろ泟 12鞁� 20攵�(霃欕秬鞁滉皠)鞐� 韺岇澊鞏挫偓鞚措摐 毂勴寘(fireside chat)鞐� 彀胳棳頃╇媹雼�.
韴瀽鞛愲摛鞚� Seer 鞗轨偓鞚错姼鞚� Investor 靹轨厴 investor.seer.bio鞐愳劀 霛检澊敫� 鞗轨簮鞀ろ姼搿� 頂勲爤鞝犿厡鞚挫厴鞚� 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟. 須岇潣 頉勳棎電� 頂勲爤鞝犿厡鞚挫厴鞚� 鞎勳勾鞚措笇 氩勳爠鞚� 鞝滉车霅� 鞓堨爼鞛呺媹雼�.
Seer (Nasdaq: SEER), une entreprise sp茅cialis茅e dans les renseignements prot茅omiques, a annonc茅 sa participation 脿 la Morgan Stanley 23rd Annual Global Healthcare Conference 脿 New York. La direction tiendra une discussion informelle (fireside chat) le 9 septembre 脿 12h20 ET.
Les investisseurs pourront acc茅der 脿 la pr茅sentation via une webdiffusion en direct dans la rubrique Investor du site de Seer 脿 l'adresse investor.seer.bio. Une version archiv茅e de la pr茅sentation sera disponible apr猫s la conf茅rence.
Seer (Nasdaq: SEER), ein Unternehmen, das sich auf proteomische Erkenntnisse spezialisiert hat, hat seine Teilnahme an der Morgan Stanley 23rd Annual Global Healthcare Conference in New York angek眉ndigt. Das Management wird am 9. September um 12:20 Uhr ET an einem Fireside-Chat teilnehmen.
Investoren k枚nnen die Pr盲sentation per Live-Webcast im Investor-Bereich der Seer-Website unter investor.seer.bio verfolgen. Nach der Konferenz wird eine archivierte Version der Pr盲sentation zur Verf眉gung gestellt.
- None.
- None.
REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY.
Seer鈥檚 management is scheduled to participate in a fireside chat on Tuesday, September 9th at 12:20 p.m. Eastern Time / 9:20 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer鈥檚 website at investor.seer.bio. An archived replay will be available on the company鈥檚 website following the conference.
About Seer
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics鈥攄elivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer鈥檚 Proteograph聽Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges that conventional methods have failed to overcome. Traditional proteomic technologies have historically struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer鈥檚 robust and scalable workflow consistently reveals biological insights that others do not. Seer鈥檚 products are for research use only and are not intended for diagnostic procedures. For more information about Seer鈥檚 differentiated approach and ongoing leadership in proteomics, visit聽.
Media Contact:
Consort Partners
Investor Inquiries:
Carrie Mendivil
FAQ
When is Seer (SEER) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors watch Seer's presentation at the Morgan Stanley Conference?
Where is the Morgan Stanley Healthcare Conference 2025 being held?
What is Seer's main business focus?
